{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:44:59Z","timestamp":1787003099852,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutations in the\n                    <jats:italic>LRRK2<\/jats:italic>\n                    gene are the most common genetic cause of familial Parkinson\u2019s Disease (LRRK2-PD) and an important risk factor for sporadic PD (sPD). Multiple clinical trials are ongoing to evaluate the benefits associated with the therapeutical reduction of LRRK2 kinase activity. In this study, we described the changes of transcriptomic profiles (whole blood mRNA levels) of LRRK2 protein interactors in sPD and LRRK2-PD cases as compared to healthy controls with the aim of comparing the two PD conditions. We went on to model the protein-protein interaction (PPI) network centred on LRRK2, which was weighted to reflect the transcriptomic changes on expression and co-expression levels of LRRK2 protein interactors. Our results showed that LRRK2 interactors present both similar and distinct alterations in expression levels and co-expression behaviours in the sPD and LRRK2-PD cases; suggesting that, albeit being classified as the same disease based on clinical features, LRRK2-PD and sPD display significant differences from a molecular perspective. Interestingly, the similar changes across the two PD conditions result in decreased connectivity within a topological cluster of the LRRK2 PPI network associated with protein metabolism\/biosynthesis and ribosomal metabolism suggesting protein homoeostasis and ribosomal dynamics might be affected in both sporadic and familial PD in comparison with controls.\n                  <\/jats:p>","DOI":"10.1038\/s41531-024-00761-8","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T10:02:00Z","timestamp":1722679320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Transcriptomics and weighted protein network analyses of the LRRK2 protein interactome reveal distinct molecular signatures for sporadic and LRRK2 Parkinson\u2019s Disease"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4520-8476","authenticated-orcid":false,"given":"Yibo","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bracher-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-0728","authenticated-orcid":false,"given":"Kirsten","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Escott-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4537-0489","authenticated-orcid":false,"given":"Patrick A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5367-4023","authenticated-orcid":false,"given":"Claudia","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"761_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0344-2","volume":"14","author":"DC Berwick","year":"2019","unstructured":"Berwick, D. C., Heaton, G. R., Azeggagh, S. & Harvey, K. LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. Mol. Neurodegener. 14, 1\u201322 (2019).","journal-title":"Mol. Neurodegener."},{"key":"761_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1010847","volume":"19","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Tissue specific LRRK2 interactomes reveal a distinct striatal functional unit. PLoS Comput. Biol. 19, 1\u201323 (2023).","journal-title":"PLoS Comput. Biol."},{"key":"761_CR3","doi-asserted-by":"crossref","unstructured":"Sanders, L., Goodson, S. D., Toste, C. M. & Gonzalez-Hunt, C. P. ATM mediated DNA double-strand breaks accumulate in LRRK2 G2019S Parkinson\u2019s disease. FASEB J. 35 (2021).","DOI":"10.1096\/fasebj.2021.35.S1.03622"},{"key":"761_CR4","doi-asserted-by":"crossref","unstructured":"Komori, T. et al. Phosphorylation of Rab29 at Ser185 regulates its localization and role in the lysosomal stress response in concert with LRRK2. J. Cell Sci. 136 (2023).","DOI":"10.1242\/jcs.261003"},{"key":"761_CR5","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.cub.2021.02.061","volume":"31","author":"C Alexander Boecker","year":"2021","unstructured":"Alexander Boecker, C., Goldsmith, J., Dou, D., Cajka, G. G. & Holzbaur, E. L. Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes graphical abstract. Curr. Biol. 31, 2140\u20132154.e6 (2021).","journal-title":"Curr. Biol."},{"key":"761_CR6","doi-asserted-by":"crossref","unstructured":"Tombesi, G. et al. LRRK2 regulates synaptic function through BDNF signaling and actin cytoskeleton. Elife 13 (2024).","DOI":"10.7554\/eLife.95987.1"},{"key":"761_CR7","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/mds.20682","volume":"20","author":"JM Bras","year":"2005","unstructured":"Bras, J. M. et al. G2019S dardarin substitution is a common cause of Parkinson\u2019s disease in a Portuguese cohort. Mov. Disord. 20, 1653\u20131655 (2005).","journal-title":"Mov. Disord."},{"key":"761_CR8","doi-asserted-by":"crossref","unstructured":"Lesage, S. et al. LRRK2 G2019S as a cause of Parkinson\u2019s disease in North African Arabs. N. Engl. J. Med. 354, 422\u2013423 (2006).","DOI":"10.1056\/NEJMc055540"},{"key":"761_CR9","doi-asserted-by":"crossref","unstructured":"Ozelius, L. J. et al. LRRK2 G2019S as a cause of Parkinson\u2019s disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424\u2013425 (2006).","DOI":"10.1056\/NEJMc055509"},{"key":"761_CR10","doi-asserted-by":"publisher","first-page":"16906","DOI":"10.1074\/jbc.M708718200","volume":"283","author":"E Greggio","year":"2008","unstructured":"Greggio, E. et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283, 16906\u201316914 (2008).","journal-title":"J. Biol. Chem."},{"key":"761_CR11","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1002\/mds.22717","volume":"25","author":"W Dauer","year":"2010","unstructured":"Dauer, W. & Ho, C. C. Y. The biology and pathology of the familial Parkinson\u2019s disease protein LRRK2. Mov. Disord. 25, S40\u2013S43 (2010).","journal-title":"Mov. Disord."},{"key":"761_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.expneurol.2014.05.025","volume":"261","author":"AR Esteves","year":"2014","unstructured":"Esteves, A. R., Swerdlow, R. H. & Cardoso, S. M. LRRK2, a puzzling protein: insights into Parkinson\u2019s disease pathogenesis. Exp. Neurol. 261, 206\u2013216 (2014).","journal-title":"Exp. Neurol."},{"key":"761_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JPD-130192","volume":"3","author":"C Pais\u00e1n-Ruiz","year":"2013","unstructured":"Pais\u00e1n-Ruiz, C., Lewis, P. A. & Singleton, A. B. LRRK2: cause, risk, and mechanism. J. Parkinsons Dis. 3, 85\u2013103 (2013).","journal-title":"J. Parkinsons Dis."},{"key":"761_CR14","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1093\/hmg\/ddv314","volume":"24","author":"AG Henry","year":"2015","unstructured":"Henry, A. G. et al. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Hum. Mol. Genet. 24, 6013\u20136028 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"761_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2017.05.013","volume":"105","author":"F Giesert","year":"2017","unstructured":"Giesert, F. et al. The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson\u2019s disease in the mouse. Neurobiol. Dis. 105, 179\u2013193 (2017).","journal-title":"Neurobiol. Dis."},{"key":"761_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"761_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-017-0010-8","volume":"3","author":"DA Cook","year":"2017","unstructured":"Cook, D. A. et al. LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. NPJ Parkinsons Dis. 3, 11 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"761_CR18","doi-asserted-by":"publisher","first-page":"eaar5429","DOI":"10.1126\/scitranslmed.aar5429","volume":"10","author":"R Di Maio","year":"2018","unstructured":"Di Maio, R. et al. LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci. Transl. Med. 10, eaar5429 (2018).","journal-title":"Sci. Transl. Med."},{"key":"761_CR19","doi-asserted-by":"publisher","first-page":"531890","DOI":"10.3389\/fnins.2020.00443","volume":"14","author":"RL Wallings","year":"2020","unstructured":"Wallings, R. L., Herrick, M. K. & Tansey, M. G. LRRK2 at the interface between peripheral and central immune function in Parkinson\u2019s. Front. Neurosci. 14, 531890 (2020).","journal-title":"Front. Neurosci."},{"key":"761_CR20","doi-asserted-by":"publisher","first-page":"105724","DOI":"10.1016\/j.nbd.2022.105724","volume":"169","author":"I Russo","year":"2022","unstructured":"Russo, I., Bubacco, L. & Greggio, E. LRRK2 as a target for modulating immune system responses. Neurobiol. Dis. 169, 105724 (2022).","journal-title":"Neurobiol. Dis."},{"key":"761_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s40478-016-0396-2","volume":"4","author":"C Bliederhaeuser","year":"2016","unstructured":"Bliederhaeuser, C. et al. LRRK2 contributes to monocyte dysregulation in Parkinson\u2019s disease. Acta Neuropathol. Commun. 4, 123 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"761_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-016-0004-y","volume":"3","author":"DA Cook","year":"2017","unstructured":"Cook, D. A. et al. LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. npj Parkinson\u2019s Dis. 3, 1\u201312 (2017).","journal-title":"npj Parkinson\u2019s Dis."},{"key":"761_CR23","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/brain\/awy077","volume":"141","author":"E Kozina","year":"2018","unstructured":"Kozina, E. et al. Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. Brain 141, 1753\u20131769 (2018).","journal-title":"Brain"},{"key":"761_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1212\/01.wnl.0000304044.22253.03","volume":"70","author":"K Haugarvoll","year":"2008","unstructured":"Haugarvoll, K. et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70, 1456\u20131460 (2008).","journal-title":"Neurology"},{"key":"761_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/jnnp.2008.162420","volume":"8","author":"DG Healy","year":"2008","unstructured":"Healy, D. G., Wood, N. W. & Schapira, A. H. V. Test for LRRK2 mutations in patients with Parkinson\u2019s disease. Pr. Neurol. 8, 381\u2013385 (2008).","journal-title":"Pr. Neurol."},{"key":"761_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/BST20180462","volume":"47","author":"JH Kluss","year":"2019","unstructured":"Kluss, J. H., Mamais, A. & Cookson, M. R. LRRK2 links genetic and sporadic Parkinson\u2019s disease. Biochem Soc. Trans. 47, 651 (2019).","journal-title":"Biochem Soc. Trans."},{"key":"761_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/mds.26161","volume":"30","author":"S Srivatsal","year":"2015","unstructured":"Srivatsal, S. et al. Cognitive profile of LRRK2-related Parkinson\u2019s disease. Mov. Disord. 30, 728\u2013733 (2015).","journal-title":"Mov. Disord."},{"key":"761_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.parkreldis.2014.09.033","volume":"21","author":"RN Alcalay","year":"2015","unstructured":"Alcalay, R. N. et al. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 21, 106\u2013110 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"761_CR29","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/acn3.772","volume":"6","author":"A Garrido","year":"2019","unstructured":"Garrido, A., Fairfoul, G., Tolosa, E. S., Mart\u00ed, M. J. & Green, A. \u03b1-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 6, 1024\u20131032 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"761_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3389\/fnins.2020.00556","volume":"14","author":"P Rivero-R\u00edos","year":"2020","unstructured":"Rivero-R\u00edos, P., Romo-Lozano, M., Fasiczka, R., Naaldijk, Y. & Hilfiker, S. LRRK2-related Parkinson\u2019s disease due to altered endolysosomal biology with variable lewy body pathology: a hypothesis. Front Neurosci. 14, 556 (2020).","journal-title":"Front Neurosci."},{"key":"761_CR31","doi-asserted-by":"publisher","first-page":"106182","DOI":"10.1016\/j.nbd.2023.106182","volume":"183","author":"L Batzu","year":"2023","unstructured":"Batzu, L. et al. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson\u2019s disease. Neurobiol. Dis. 183, 106182 (2023).","journal-title":"Neurobiol. Dis."},{"key":"761_CR32","doi-asserted-by":"crossref","unstructured":"Tolosa, E., Vila, M., Klein, C. & Rascol, O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat. Rev. Neurol. 16, 97\u2013107 (2020).","DOI":"10.1038\/s41582-019-0301-2"},{"key":"761_CR33","doi-asserted-by":"crossref","unstructured":"Breckenridge, C. B., Berry, C., Chang, E. T., Sielken, R. L. & Mandel, J. S. Association between Parkinson\u2019s Disease and Cigarette Smoking, Rural Living, Well-water Consumption, Farming and Pesticide Use: Systematic Review and Meta-analysis. PLoS ONE 11 (2016).","DOI":"10.1371\/journal.pone.0151841"},{"key":"761_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-105","volume":"8","author":"S Levesque","year":"2011","unstructured":"Levesque, S., Surace, M. J., McDonald, J. & Block, M. L. Air pollution & the brain: subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease. J. Neuroinflammation 8, 105 (2011).","journal-title":"J. Neuroinflammation"},{"key":"761_CR35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/mds.28922","volume":"37","author":"H Murata","year":"2022","unstructured":"Murata, H., Barnhill, L. M. & Bronstein, J. M. Air pollution and the risk of Parkinson\u2019s disease: a review. Mov. Disord. 37, 894\u2013904 (2022).","journal-title":"Mov. Disord."},{"key":"761_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yrtph.2018.05.005","volume":"96","author":"D Yan","year":"2018","unstructured":"Yan, D., Zhang, Y., Liu, L., Shi, N. & Yan, H. Pesticide exposure and risk of Parkinson\u2019s disease: dose-response meta-analysis of observational studies. Regul. Toxicol. Pharm. 96, 57\u201363 (2018).","journal-title":"Regul. Toxicol. Pharm."},{"key":"761_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ana.25726","volume":"88","author":"DL White","year":"2020","unstructured":"White, D. L. et al. Post-traumatic stress disorder is associated with further increased Parkinson\u2019s disease risk in veterans with traumatic brain injury. Ann. Neurol. 88, 33\u201341 (2020).","journal-title":"Ann. Neurol."},{"key":"761_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s10038-022-01058-5","volume":"68","author":"M Funayama","year":"2022","unstructured":"Funayama, M., Nishioka, K., Li, Y. & Hattori, N. Molecular genetics of Parkinson\u2019s disease: Contributions and global trends. J. Hum. Genet. 68, 125\u2013130 (2022). 2022 68:3.","journal-title":"J. Hum. Genet."},{"key":"761_CR39","doi-asserted-by":"crossref","unstructured":"Manzoni, C., Denny, P., Lovering, R. C. & Lewis, P. A. Computational analysis of the LRRK2 interactome. PeerJ 2015 (2015).","DOI":"10.7717\/peerj.778"},{"key":"761_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","volume":"16","author":"EK Tan","year":"2020","unstructured":"Tan, E. K. et al. Parkinson disease and the immune system\u2014associations, mechanisms and therapeutics. Nat. Rev. Neurol. 16, 303\u2013318 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"761_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-015-0257-4","volume":"3","author":"P Garcia-Esparcia","year":"2015","unstructured":"Garcia-Esparcia, P. et al. Altered machinery of protein synthesis is region- and stage-dependent and is associated with \u03b1-synuclein oligomers in Parkinson\u2019s disease. Acta Neuropathologica Commun. 3, 1\u201325 (2015).","journal-title":"Acta Neuropathologica Commun."},{"key":"761_CR42","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.3390\/cells9122580","volume":"9","author":"S Plum","year":"2020","unstructured":"Plum, S. et al. Proteomic characterization of synaptosomes from human substantia Nigra indicates altered mitochondrial translation in Parkinson\u2019s disease. Cells 9, 2580 (2020).","journal-title":"Cells"},{"key":"761_CR43","doi-asserted-by":"publisher","first-page":"105298","DOI":"10.1016\/j.nbd.2021.105298","volume":"153","author":"Y Chu","year":"2021","unstructured":"Chu, Y. & Kordower, J. H. GDNF signaling in subjects with minimal motor deficits and Parkinson\u2019s disease. Neurobiol. Dis. 153, 105298 (2021).","journal-title":"Neurobiol. Dis."},{"key":"761_CR44","doi-asserted-by":"publisher","first-page":"368915","DOI":"10.3389\/fnagi.2018.00156","volume":"10","author":"Y Qian","year":"2018","unstructured":"Qian, Y. et al. Detection of microbial 16S rRNA gene in the blood of patients with Parkinson\u2019s disease. Front. Aging Neurosci. 10, 368915 (2018).","journal-title":"Front. Aging Neurosci."},{"key":"761_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00554-5","volume":"18","author":"JE Tomkins","year":"2020","unstructured":"Tomkins, J. E. et al. PINOT: An intuitive resource for integrating protein-protein interactions. Cell Commun. Signal. 18, 92 (2020).","journal-title":"Cell Commun. Signal."},{"key":"761_CR46","doi-asserted-by":"publisher","first-page":"D408","DOI":"10.1093\/nar\/gkw985","volume":"45","author":"G Alanis-Lobato","year":"2017","unstructured":"Alanis-Lobato, G., Andrade-Navarro, M. A. & Schaefer, M. H. HIPPIE v2.0: enhancing meaningfulness and reliability of protein-protein interaction networks. Nucleic Acids Res. 45, D408\u2013D414 (2017).","journal-title":"Nucleic Acids Res."},{"key":"761_CR47","doi-asserted-by":"publisher","first-page":"D567","DOI":"10.1093\/nar\/gkx1116","volume":"46","author":"Y Hu","year":"2018","unstructured":"Hu, Y. et al. Molecular Interaction Search Tool (MIST): An integrated resource for mining gene and protein interaction data. Nucleic Acids Res. 46, D567\u2013D574 (2018).","journal-title":"Nucleic Acids Res."},{"key":"761_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).","journal-title":"BMC Bioinform."},{"key":"761_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1\u201321 (2014).","journal-title":"Genome Biol."},{"key":"761_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-023-00614-w","volume":"10","author":"BJ Whittle","year":"2024","unstructured":"Whittle, B. J. et al. Early-stage idiopathic Parkinson\u2019s disease is associated with reduced circular RNA expression. npj Parkinson\u2019s Dis. 10, 1\u201314 (2024).","journal-title":"npj Parkinson\u2019s Dis."},{"key":"761_CR51","first-page":"5","volume":"69","author":"MEJ Newman","year":"2004","unstructured":"Newman, M. E. J. Fast algorithm for detecting community structure in networks. Phys. Rev. E: Stat. Phys. Plasmas Fluids Relat. Interdiscip. Top. 69, 5 (2004).","journal-title":"Phys. Rev. E: Stat. Phys. Plasmas Fluids Relat. Interdiscip. Top."},{"key":"761_CR52","doi-asserted-by":"publisher","first-page":"709","DOI":"10.12688\/f1000research.24956.2","volume":"9","author":"H Peterson","year":"2020","unstructured":"Peterson, H., Kolberg, L., Raudvere, U., Kuzmin, I. & Vilo, J. gprofiler2\u2014an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Research 9, 709 (2020).","journal-title":"F1000Research"},{"key":"761_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-019-0074-8","volume":"5","author":"R Balestrino","year":"2019","unstructured":"Balestrino, R. et al. Applications of the European Parkinson\u2019s Disease Association sponsored Parkinson\u2019s Disease Composite Scale (PDCS). npj Parkinson\u2019s Dis. 5, 1\u20137 (2019). 2019 5:1.","journal-title":"npj Parkinson\u2019s Dis."},{"key":"761_CR54","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mdc3.12476","volume":"4","author":"M Skorvanek","year":"2017","unstructured":"Skorvanek, M. et al. Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration. Mov. Disord. Clin. Pr. 4, 536\u2013544 (2017).","journal-title":"Mov. Disord. Clin. Pr."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00761-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00761-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00761-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T11:04:46Z","timestamp":1722683086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00761-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1038\/s41531-024-00761-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}